(Press-News.org) SAN ANTONIO — The presence of one to four circulating tumor cells (CTCs) in the blood of early-stage breast cancer patients almost doubled patient's risk of cancer relapse and death, and five or more CTCs increased recurrence by 400 percent and death by 300 percent, according to Phase III results of the SUCCESS trial. These cells were found in patients after surgery but before chemotherapy treatment.
Results of this study were presented at the 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium, held Dec. 8-12, 2010, and demonstrate the value of CTCs in early breast cancer, independent of estrogen-receptor or HER2 status and before use of adjuvant therapy.
The benefit of using CTCs to predict risk for recurrence and death in metastatic breast cancer patients has been shown in a number of studies, and use of a CTC test in metastatic breast cancer has been approved by the Food and Drug Administration.
The CTCs found in this study are likely evidence that a tumor is shedding breast cancer cells, said lead researcher Brigitte Rack, M.D., head of the department of gynecological oncology at the Women's Hospital at the University of Munich, Germany. "The CTCs might have been released from the primary tumor before these patients underwent surgery, and the expression of stem cell markers on disseminated tumors cells has been shown by several groups."
Survival of these CTCs after chemotherapy further suggests they are cancer stem cells, Rack added.
Researchers with this study are testing the effectiveness of two different chemotherapy regimens and extended adjuvant bisphosphonate treatment in early breast cancer. SUCCESS' efficacy data are expected to be released next year.
Results of this study showed that 21.5 percent of patients had one or more CTC in their blood before the start of adjuvant treatment. These patients were more frequently node-positive, but no other linkage could be made with tumor size or grade or HER2 status.
Breast cancer recurred in 114 patients, and 66 patients died. Being CTC-positive was a significant independent predictor for both disease-free and overall survival. Patients with one to four CTCs had an 88 percent increased risk of early breast cancer recurrence and a 91 percent increased risk of death from breast cancer, according to Rack.
Prognosis was worse in patients with five or more CTCs; these patients had a fourfold risk of cancer recurrence and a threefold risk for death from the disease.
"Our study suggests testing CTCs may prove to be important to help individualize therapy for early-stage breast cancer where no measurable tumor is present," she said. "Patients who seem to be at high risk due to CTC may benefit from additional treatment options, and those that don't have CTCs may be spared side effects of some treatments."
She added, however, that prospectively randomized trials are necessary to show an improvement of survival based on CTC diagnostics. Trials testing this notion are either ongoing or about to start in Europe and the United States, according to Rack.
###
Follow the AACR on Twitter @AACR, and throughout the meeting using the hash tag #SABCS.
Recordings of the teleconferences and video interviews with researchers will posted to the AACR website throughout the meeting: http://www.aacr.org/page23506.aspx.
The mission of the CTRC-AACR San Antonio Breast Cancer Symposium is to produce a unique and comprehensive scientific meeting that encompasses the full spectrum of breast cancer research, facilitating the rapid translation of new knowledge into better care for breast cancer patients. The Cancer Therapy & Research Center (CTRC) at The University of Texas Health Science Center at San Antonio, the American Association for Cancer Research (AACR) and Baylor College of Medicine are joint sponsors of the San Antonio Breast Cancer Symposium. This collaboration utilizes the clinical strengths of the CTRC and Baylor, and the AACR's scientific prestige in basic, translational and clinical cancer research to expedite the delivery of the latest scientific advances to the clinic. The 33rd annual symposium is expected to draw nearly 9,000 participants from more than 90 countries.
Circulating tumor cells predicted recurrence, death in patients with early-stage breast cancer
2010-12-11
ELSE PRESS RELEASES FROM THIS DATE:
High CTC levels predicted poor outcome in metastatic breast cancer
2010-12-11
SAN ANTONIO — A high level of circulating tumor cells (CTCs) — cells that have detached from a tumor and are circulating in the body through the blood — are an independent prognostic marker in metastatic breast cancer as first-line therapy. In addition, persistence of high CTC level during therapy was found to be an early marker of poor outcome.
"This is the largest, prospective series validating the prognostic value of CTCs in first-line chemotherapy metastatic breast cancer, independently from serum tumor markers for overall survival," said Jean-Yves Pierga, M.D., Ph.D., ...
Denosumab delayed time to first skeletal-related side effect
2010-12-11
SAN ANTONIO — For patients with breast cancer and bone metastases, denosumab delayed skeletal-related side effects five months longer compared to those on zoledronic acid, according to results presented at the 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium, held Dec. 8-12.
"The average life expectancy of patients with metastatic breast cancer is approximately 2.5 years, so if you can prolong the time without a skeletal-related event by five months, you are substantially benefiting the patient," said Alison T. Stopeck, M.D., associate professor of medicine ...
CTCs predict poor outcome from blood stem cell transplantation therapy for metastatic breast cancer
2010-12-11
SAN ANTONIO — Metastatic breast cancer patients who had circulating tumor cells (CTCs) in their blood before or after high-dose chemotherapy (HDCT) followed by autologous stem cell transplantation had poor outcomes, according to researchers from the University of Texas MD Anderson Cancer Center.
Patients with CTCs in their blood before chemotherapy treatment had reduced survival and those with these cells in their blood after the stem cell transplant recurred faster and died earlier. These findings were presented at the 33rd Annual CTRC-AACR San Antonio Breast Cancer ...
Phase III efficacy data on bevacizumab plus chemotherapy in early breast cancer to be presented
2010-12-11
SAN ANTONIO — Results of the GeparQuinto study, randomized Phase III efficacy data on the use of bevacizumab plus chemotherapy to treat women with early breast cancer will be presented at the 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium.
Gunter von Minckwitz, M.D., Ph.D., managing director of the German Breast Group, and colleagues are conducting final analyses on efficacy data from this study, which will detail the early treatment of more than 1,900 patients with HER2-negative breast cancer treated with chemotherapy with or without bevacizumab.
"So far, ...
FReD can help explain how a bee sees!
2010-12-11
Bees can see colours but they perceive the world differently to us, including variations in hue that we cannot ourselves distinguish.
Researchers at Queen Mary, University of London and Imperial College London have developed FReD – the Floral Reflectance Database – which holds data on what colours flowers appear to be, to bees. The development of the catalogue, which has involved a collaborative effort between researchers at two Schools at Queen Mary is reported in the journal PLoS ONE.
The work addresses the existing issue that records of flower colours do not take ...
Boxing -- bad for the brain
2010-12-11
Up to 20% of professional boxers develop neuropsychiatric sequelae. But which acute complications and which late sequelae can boxers expect throughout the course of their career? These are the questions studied by Hans Förstl from the Technical University Munich and his co-authors in the current issue of Deutsches Ärzteblatt International (Dtsch Arztebl Int 2010; 107[47]: 835-9).
Their evaluation of the biggest studies on the subject of boxers' health in the past 10 years yielded the following results: The most relevant acute consequence is the knock-out, which conforms ...
Wind and water have shaped Schiaparelli on Mars
2010-12-11
The small crater embedded in the northwestern rim of the Schiaparelli impact basin features prominently in this new image from ESA's Mars Express. All around is evidence for past water and the great martian winds that periodically blow.
Schiaparelli is a large impact basin about 460 km in diameter located in the eastern Terra Meridiani region of the equator of Mars. The centre of the basin lies at about 3°S/17°E and is named after the Italian astronomer Giovanni Schiaparelli (1835�). Although he also studied Mercury and Venus, he is best known for his observations ...
Beyond bars
2010-12-11
Despite threats of violence, imprisonment and death, writers around the world continue to fight to make their voices heard. The latest issue of Index on Censorship pays tribute to one of the world's longest running campaigns for free expression, English PEN's Writers in Prison Committee (WiPC). Founded in 1960, the WiPC supports and protects writers facing persecution around the globe. Contributors to Beyond Bars – including award-winning authors Margaret Atwood, Sir Tom Stoppard and William Boyd – highlight the vital role writers can play in supporting their colleagues. ...
Assessing the seismic hazard of the central eastern United States
2010-12-11
As the U.S. policy makers renew emphasis on the use of nuclear energy in their efforts to reduce the country's oil dependence, other factors come into play. One concern of paramount importance is the seismic hazard at the site where nuclear reactors are located.
Russell A. Green, associate professor of civil and environmental engineering at Virginia Tech, spent five years as an earthquake engineer for the U.S. Defense Nuclear Facilities Safety Board in Washington, D.C., prior to becoming a university professor. Part of his responsibility at the safety board was to perform ...
Iron legacy leaves soil high in manganese
2010-12-11
Iron furnaces that once dotted central Pennsylvania may have left a legacy of manganese enriched soils, according to Penn State geoscientists. This manganese can be toxic to trees, especially sugar maples, and other vegetation.
The research, which quantified the amounts of manganese in soil core samples, was part of work done at the Shale Hills Critical Zone Observatory funded by the National Science Foundation.
"Our group's focus was to study the soil chemistry," said Elizabeth M. Herndon, graduate student in geosciences. "We saw excess manganese in the soil and ...